<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=412980&amp;fmt=gif">

LSX: THE COMMUNITY FOR LIFE SCIENCE EXECUTIVES

LSX, formerly Biotech and Money, is an influential community of senior life science decision makers. We connect senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. We achieve this through a programme of high-level conferences and networking events, via content that showcases and shares the expertise of investors, senior leaders and industry stakeholders, as well as through bespoke initiatives.

Upcoming Events
Blog and Content
Our Community

OUR CONFERENCE AND COMMUNITY BRANDS

LSX World Congress.png
Investival Header.png
LSX Nordic Congress-1.png
LSX World Congress USA
LSX CEO Forum
LSX Connect
LSX Investor Club

INVESTMENT AND IPOS

Have your say on life sciences investment trends

LSX, formerly Biotech and Money, is conducting the 3rd Investor Perception ...

Read More

Forendo Pharma receives €4m boost to progress women’s health programmes

Key learnings: Vesalius BioCapital III Partners invested €4 million in Finl...

Read More

Evox Therapeutics raises £35.5m Series B to advance exosome technology

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More
View More

M&A AND DEAL MAKING

Reviewing life sciences deal trends

For the first seven months of this year (to July) our Deal Watch analysis o...

Read More

Navigating M&A transactions in life sciences

An acquisition in the life sciences sector raises various issues, some of w...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

R&D TO COMMERCIALISATION

What life sciences companies need to know about pre-approval access

Pre-approval access is evolving at a rapid pace. Mark Corbett (pictured), E...

Read More

Evox Therapeutics raises £35.5m Series B to advance exosome technology

Key learnings: UK biotech Evox Therapeutics recently announced its £35.5 mi...

Read More
View More

IP, REGULATION AND COMPLIANCE

Brexit: finite uncertainty

One might think that planning for uncertainty is something that biotech fir...

Read More

C-Suite challenges and how intellectual property can help meet them

The 2018 C-Suite Challenges in Life Sciences Survey from Biotech & Money/LS...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More
View More

TALENT AND EXECUTIVE STRATEGY

Bolstering women in the C-suite and boardroom

The leadership landscape within life sciences is beginning to change. More ...

Read More

C-suite survey uncovers life sciences challenges

For more than three-quarters (78%) of C-level respondents in the life scien...

Read More

The talent challenge in life sciences

A disconcerting 59% of investor respondents consider under one quarter of t...

Read More
View More

COMMUNITY PARTNERS AND PREMIUM COMMUNITY MEMBERS

Alacrita
allen and overy
Appleyard Lees
barclays
Boult Wade Tennant
Cancer Research UK.jpg
capitalcell.png
CMS Cameron Mckenna.png
covington.png
Dyadic.png
eqs.png
gje.png
Gallagher.png
Horizon.png
illumina-logo.svg
Inceptua
Marks & Clerk Intellectual Property Services.jpeg
Storm Therapeutics.png
Xplico.png